Cost-effectiveness of universal pneumococcal vaccination for infants in Italy (Q44021881)

29 November 2017

title

Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. (English)

1 reference

29 November 2017

0 references

Marchetti M

1

1 reference

29 November 2017

Colombo GL

series ordinal

2

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

29 November 2017

1 reference

29 November 2017

volume

23

1 reference

29 November 2017

issue

37

1 reference

29 November 2017

page(s)

4565-4576

1 reference

Pattern of bacterial meningitis in Italy, 1994.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Antibiotic Susceptibility and Serotype Distribution ofStreptococcus pneumoniaeCausing Meningitis in Italy, 1997–1999

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Impact of the pneumococcal conjugate vaccine on otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Inferring the potential success of pneumococcal vaccination in Italy: serotypes and antibiotic resistance of Streptococcus pneumoniae isolates from invasive diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Markov models in medical decision making: a practical guide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

New rapid antigen test for diagnosis of pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Paediatric, invasive pneumococcal disease in Switzerland, 1985-1994. Swiss Pneumococcal Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Pneumococcal bacteremia in childhood: a 6-year experience in a community hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Incidence of acute otitis media

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

inferred from DOI database lookup

7 January 2021

based on heuristic

Use of diagnostic clusters to assess the economic consequences of rhinopharyngitis in children in Italy and France during the winter. Rhinitis Survey Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Characteristics ofStreptococcus pneumoniaeand Atypical Bacterial Infections in Children 2–5 Years of Age with Community‐Acquired Pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Hospital admissions for pneumonia in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Risk of bacteremia in young children with pneumonia treated as outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Bacteremic pneumococcal pneumonia in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Gains in life expectancy from medical interventions--standardizing data on outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

An economic evaluation of universal pertussis vaccination in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

The use of hepatitis a vaccination in Italy: an economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Observed costs and health care use of children in a randomized controlled trial of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

An international medico-economic survey of 2007 children with recurrent nasopharyngitis and acute otitis media. Preliminary bindings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.033

10.1016/J.VACCINE.2005.04.033

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference